Table 2.
Baseline characteristics: cangrelor vs clopidogrel according to PAD history.
| PAD |
No PAD |
|||||
|---|---|---|---|---|---|---|
| Cangrelor |
Clopidogrel |
P-value | Cangrelor |
Clopidogrel |
P-value | |
| N = 889 | N = 831 | N = 11,384 | N = 11,418 | |||
| Demographic | ||||||
| Age-yr. | ||||||
| Median | 68.0 | 68.0 | 0.96 | 63.0 | 63.0 | 0.40 |
| Interquartile range | 60, 75 | 61.75 | 55, 71 | 55, 71 | ||
| Female sex, n (%) | 28.8 | 30.9 | 0.33 | 27.5 | 27.6 | 0.89 |
| Weight – kg | ||||||
| Median | 83.0 | 83.6 | 0.48 | 83.0 | 83.0 | 0.97 |
| Interquartile range | 72, 94 | 72, 95 | 72, 95 | 72, 95 | ||
| Medical history, n (%) | ||||||
| Diabetes mellitus | 44.2 | 46.0 | 0.45 | 28.1 | 28.6 | 0.42 |
| Current smoker | 26.9 | 30.8 | 0.08 | 29.3 | 29.3 | 0.99 |
| Hypertension | 86.1 | 88.1 | 0.23 | 75.2 | 74.3 | 0.11 |
| Hyperlipidemia | 83.3 | 80.7 | 0.16 | 63.3 | 63.1 | 0.82 |
| Prior stroke or TIA | 10.9 | 13.6 | 0.09 | 4.7 | 4.4 | 0.18 |
| Prior myocardial infarction | 31.2 | 34.0 | 0.21 | 21.6 | 22.6 | 0.07 |
| Prior PTCA or PCI | 39.4 | 39.9 | 0.82 | 21.7 | 22.6 | 0.10 |
| CABG | 26.5 | 24.7 | 0.40 | 9.2 | 8.9 | 0.40 |
| Heart failure | 21.5 | 19.2 | 0.25 | 7.5 | 7.9 | 0.25 |
| Procedural | ||||||
| Indication, n (%)a | 0.57 | 0.18 | ||||
| Stable angina | 40.3 | 40.1 | 30.8 | 30.0 | ||
| NSTE ACS | 52.0 | 53.4 | 57.6 | 57.7 | ||
| STEMI | 7.8 | 6.5 | 11.6 | 12.3 | ||
| Antithrombotic, n (%) | ||||||
| Aspirinb | 93.5 | 93.9 | 0.74 | 94.0 | 93.3 | 0.02 |
| Clopidogrel, loading dose (planned) | 0.17 | 0.74 | ||||
| 300 mg | 10.2 | 8.3 | 11.4 | 11.6 | ||
| 600 mg | 89.8 | 91.7 | 88.6 | 88.4 | ||
| Low-molecular-weight heparinb | 21.3 | 21.2 | 0.97 | 23.1 | 23.5 | 0.44 |
| Unfractionated heparinb | 71.7 | 70.8 | 0.68 | 74.2 | 74.4 | 0.74 |
| Fondaparinuxb | 1.5 | 1.3 | 0.81 | 2.3 | 2.1 | 0.37 |
| Bivalirudinb | 29.5 | 33.0 | 0.12 | 24.6 | 24.8 | 0.73 |
| Glycoprotein IIb/IIIa inhibitor | 9.8 | 11.1 | 0.38 | 12.5 | 13.3 | 0.11 |
| Stent type, n (%) | 0.39 | 0.70 | ||||
| Only drug eluting stent | 473 (53.2) | 447 (53.8) | 5729 (50.3) | 5722 (50.1) | ||
| Only bare metal stent | 320 (36.0) | 304 (36.6) | 4697 (41.3) | 4776 (41.8) | ||
| Both | 37 (4.2) | 22 (2.6) | 316 (2.8) | 299 (2.6) | ||
| Neither | 59 (6.6) | 58 (7.0) | 642 (5.6) | 621 (5.4) | ||
| PCI duration in mins | 0.14 | 0.57 | ||||
| Mean ± SD | 24.2 ± 19.9 | 25.7 ± 21.8 | 24.8 ± 20.2 | 24.9 ± 20.4 | ||
| Median (Q1,Q3) | 19.0 (10,32) | 20.0 (11,33) | 20.0 (11,32) | 20.0 (11,32) | ||
| Number of vessels treated | 0.43 | 0.74 | ||||
| Mean ± SD | 1.2 ± 0.5 | 1.2 ± 0.5 | 1.2 ± 0.4 | 1.2 ± 0.4 | ||
PAD, peripheral artery disease; TIA, transient ischemic attack; PTCA, percutaneous transluminal coronary angioplasty; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; NSTE ACS, non ST-elevation acute coronary syndrome; STEMI, ST-elevation myocardial infarction.
a
As determined by statistical analysis, taking into account clinical study data available after time of randomization.
b
Prior or procedural.